CSF1R Inhibition in Patients With Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase 1 Study of Vimseltinib.

André B P van Kuilenburg Albiruni Abdul Razak Matthew H Taylor Todd M Bauer Breelyn A Wilky Javier Martín-Broto Alejandro Falcón Gonzalez Piotr Lukasz Rutkowski Bartlomiej Szostakowski Thierry Alcindor Ramy R Saleh Sofia Genta Silvia Stacchiotti Michiel Adreanus van de Sande Andrew J Wagner Nicholas M Bernthal Lara E Davis Jacqueline Vuky Christopher Tait Bahar Matin Supraja Narasimhan Maitreyi G Sharma Rodrigo Ruiz-Soto Matthew L Sherman William D Tap

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

Vimseltinib demonstrated long-term tolerability, manageable safety, dose-dependent exposure, and robust antitumor activity in patients with TGCT whose disease is not amenable to surgery.

Keyphrases

giant cell
open label
minimally invasive
coronary artery bypass
placebo controlled
double blind
clinical trial
surgical site infection
randomized controlled trial
study protocol